These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 17158893)

  • 1. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
    Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
    Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection.
    Shabani SH; Zakeri S; Salmanian AH; Amani J; Mehrizi AA; Snounou G; Nosten F; Andolina C; Mourtazavi Y; Djadid ND
    Mol Immunol; 2017 Oct; 90():158-171. PubMed ID: 28800475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population.
    Cheng Y; Ito D; Sattabongkot J; Lim CS; Kong DH; Ha KS; Wang B; Tsuboi T; Han ET
    Malar J; 2013 Sep; 12():323. PubMed ID: 24034268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trials for the co-expression of the merozoite surface protein-1 and circumsporozoite protein genes of Plasmodium vivax.
    Lee C; Chung KW; Kim TS; Choi KM; Choi YK; Chung NJ; Rhie HG; Lee HS; Lee SJ; Lee HW
    Exp Parasitol; 2011 Nov; 129(3):227-33. PubMed ID: 21907198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
    Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
    Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
    de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
    Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
    Mizutani M; Fukumoto S; Soubeiga AP; Soga A; Iyori M; Yoshida S
    Malar J; 2016 Apr; 15(1):251. PubMed ID: 27129682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
    Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
    Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the humoral response to repeat and non-repeat sequences of the circumsporozoite protein of Plasmodium vivax using novel adjuvant and delivery systems.
    Thomas BE; Manocha M; Haq W; Adak T; Pillai CR; Rao DN
    Ann Trop Med Parasitol; 2001 Jul; 95(5):451-72. PubMed ID: 11487368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.
    Bell BA; Wood JF; Bansal R; Ragab H; Cargo J; Washington MA; Wood CL; Ware LA; Ockenhouse CF; Yadava A
    Vaccine; 2009 Feb; 27(9):1448-53. PubMed ID: 19138714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
    Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
    Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-dose viral-vectored
    Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
    Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.
    Céspedes N; Arévalo-Herrera M; Felger I; Reed S; Kajava AV; Corradin G; Herrera S
    Vaccine; 2013 Oct; 31(42):4923-30. PubMed ID: 23954378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates.
    González JM; Hurtado S; Arévalo-Herrera M; Herrera S
    Mem Inst Oswaldo Cruz; 2001 Jul; 96(5):709-12. PubMed ID: 11500776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
    Bennett JW; Yadava A; Tosh D; Sattabongkot J; Komisar J; Ware LA; McCarthy WF; Cowden JJ; Regules J; Spring MD; Paolino K; Hartzell JD; Cummings JF; Richie TL; Lumsden J; Kamau E; Murphy J; Lee C; Parekh F; Birkett A; Cohen J; Ballou WR; Polhemus ME; Vanloubbeeck YF; Vekemans J; Ockenhouse CF
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004423. PubMed ID: 26919472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.
    Shabani SH; Zakeri S; Mortazavi Y; Mehrizi AA
    Med Microbiol Immunol; 2019 Dec; 208(6):731-745. PubMed ID: 31025102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
    Yadava A; Nurmukhambetova S; Pichugin AV; Lumsden JM
    J Infect Dis; 2012 May; 205(9):1456-63. PubMed ID: 22457289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.